Maximilian BrinkhausSenior Scientist II at argenx, BelgiumSpeaker
Profile
Before joining argenx, I researched the impact of IgG Fc and format engineering on Fc receptor interactions and the downstream effects on IgG cellular trafficking in close collaboration with the company. I officially joined argenx in 2022, where I now serve as a group lead in R&D, leading antibody development projects from selections to IND enabling studies.
Agenda Sessions
FcγRs mediate IgG internalization and delivery to FcRn
, 15:30View Session
